Please use this identifier to cite or link to this item:
Title: Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome
Authors: Dziekan, Jerzy Michal
Wirjanata, Grennady
Dai, Lingyun
Go, Ka Diam
Yu, Han
Lim, Yan Ting
Chen, Liyan
Wang, Loo Chien
Puspita, Brenda
Prabhu, Nayana
Sobota, Radoslaw M.
Nordlund, Pär
Bozdech, Zbynek
Keywords: Science::Biological sciences
Issue Date: 2020
Source: Dziekan, J. M., Wirjanata, G., Dai, L., Go, K. D., Yu, H., Lim, Y. T., Chen, L., Wang, L. C., Puspita, B., Prabhu, N., Sobota, R. M., Nordlund, P. & Bozdech, Z. (2020). Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome. Nature Protocols, 15(6), 1881-1921.
Project: MOH/IAFCAT2/004/2015
Journal: Nature Protocols
Abstract: Despite decades of research, little is known about the cellular targets and the mode of action of the vast majority of antimalarial drugs. We recently demonstrated that the cellular thermal shift assay (CETSA) protocol in its two variants: the melt curve and the isothermal dose-response, represents a comprehensive strategy for the identification of antimalarial drug targets. CETSA enables proteome-wide target screening for unmodified antimalarial compounds with undetermined mechanisms of action, providing quantitative evidence about direct drug-protein interactions. The experimental workflow involves treatment of P. falciparum-infected erythrocytes with a compound of interest, heat exposure to denature proteins, soluble protein isolation, enzymatic digestion, peptide labeling with tandem mass tags, offline fractionation, and liquid chromatography-tandem mass spectrometry analysis. Methodological optimizations necessary for the analysis of this intracellular parasite are discussed, including enrichment of parasitized cells and hemoglobin depletion strategies to overcome high hemoglobin abundance in the host red blood cells. We outline an effective data processing workflow using the mineCETSA R package, which enables prioritization of drug-target candidates for follow-up studies. The entire protocol can be completed within 2 weeks.
ISSN: 1754-2189
DOI: 10.1038/s41596-020-0310-z
Rights: © 2020 Nature Protocols. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SBS Journal Articles

Page view(s)

Updated on May 20, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.